Google News – Pharmaceuticals External News
Life Sciences & Pharma Articles
Google News – Pharmaceuticals External News
Recursion Pharmaceuticals (RXRX) Reports Weaker Q2 Results, Is The Valuation Gap Too Wide? - simplywall.st
Google News – Pharmaceuticals External News
Bank of New York Mellon Corp Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH - marketbeat.com
Google News – Pharmaceuticals External News
Telix Pharmaceuticals (ASX:TLX) Nears A Pixclara Decision, Is The Upside Already Priced In? - simplywall.st
Google News – Pharmaceuticals External News
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Google News – Biotech Funding External News
Big pharma eyes Australian biotech as $300b patent cliff looms - AFR
Google News – Pharmaceuticals External News
ANI Pharmaceuticals (ANIP), Why Is Fresh Attention Building Around It? - simplywall.st
Google News – Pharmaceuticals External News
ACADIA Pharmaceuticals (ACAD) Wins EU Approval For DAYBU, Is The 16% Upside Still There? - simplywall.st
Google News – Clinical Trials External News
Arthritis Drug Restores Up to 100% of Hair in Patients With Severe Alopecia - ScienceAlert
Google News – Pharmaceuticals External News
Did NMPA’s Acceptance of HS-20093 Just Shift Hansoh Pharmaceutical Group's (SEHK:3692) Oncology Narrative? - simplywall.st
Google News – Pharmaceuticals External News
Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales - simplywall.st
Google News – Clinical Trials External News
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines - BioPharma Dive
Google News – Pharmaceuticals External News
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Aspire Trial Failure And Expense Cut Plans - simplywall.st
Google News – Clinical Trials External News
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem. - Pharmafile
Google News – Pharmaceuticals External News